Good morning, and welcome to the Opsens Q4 F iscal Year 2021 Financial Results. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your touchtone phone. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Robert Blum with Lytham Partners. Please go ahead. All right, thank you very much, and thank you all for joining us today for The Opsens Q4 and Fiscal Year 2021 Conference Call. With us on the call representing the company today are Mr. Louis Laflamme, Opsens President and Chief Executive Officer, and Robin Villeneuve, Opsens' Chief Financial Officer. At the conclusion of today's prepared remarks, we will open the call for a question-and-answer session. Before we begin with prepared remarks, just a couple of comments. Today's call will contain forward-looking statements that are based on current assumptions and subject to risks and uncertainties that could cause actual results to differ materially from those projected, and the company undertakes no obligation to update these statements except as required by law. Information about these results and uncertainties are included in the company's filings, as well as periodic filings with regulators in Canada and the United States, which can be found on SEDAR and the Opsens website. Today's discussion will include adjusted financial measures, which are non-IFRS measures. These should be considered as a supplement to, and not a substitute for, IFRS financial measures. Finally, today's event is being recorded and will be available for replay through both the webcast and conference call dial-in information provided in the press release. With that said, let me turn the call over to Louis Laflamme, President and Chief Executive Officer for Opsens. Louis, please proceed. Thank you, Robert, and good morning to all of you. We are excited to speak with you today for our Q4 and fiscal year 2021 conference call. Let me also take a minute to greet the French-speaking audience. [Non-English Content] Let's move into the highlights. From a revenue standpoint, I'm pleased with the operating results for the fiscal year 2021 as we reported double-digit top-line growth across the board, highlighted by record annual revenues of $34.5 million, an increase of 17% compared to last year. The growth in revenues was led by our OptoWire product for coronary artery disease, with sales of $22.9 million, up 22% from last year. This was a record year for the OptoWire sale, highlighted by strong growth in the U.S., where OptoWire sales grew 42%. During the Q4, revenue was $8.1 million, an increase of 7% compared to the Q4 a year ago. However, below peak sales we delivered in the Q2 and Q3 2021. I will expand upon some of the drivers on this in a moment. However, our indications show that this was pandemic related due to the third wave and supply chain challenges. We believe normal quarterly revenue growth will come back during fiscal year 2022. Transitioning to our pipeline, we made tremendous progress on our TAVR development program, moving us increasingly closer to our goal to commercialize the industry's first-ever pressure guidewire designed to both deliver a valvular prosthesis while allowing for continuous hemodynamic pressure measurement during a TAVR procedure, a significant competitive advantage for our SavvyWire. Importantly, a key milestone was achieved this week with the successful completion of our first-in-man study with the SavvyWire. I will expand upon this as well as our upcoming expectations and milestones further in a moment. Simply put, we are now closer than ever to entering the massive TAVR market, currently estimated at $5 billion and expected to reach $8 billion by 2025, with what we believe is one of the industry's most innovative products that will drive future revenue for Opsens. I think it's important to remind everyone that Opsens is in the best financial position in the history of the company from a balance sheet perspective. We have the financial flexibility to strategically execute our growth strategy. At the end of August 2021, Opsens had more than CAD 38 million in cash on the balance sheet. With that as a high-level overview, let's jump into more specifics. Let us start with the OptoWire. Sales within our coronary artery disease business are what we refer to as FFR and dPR, were CAD 22.9 million during the year, a 22% increase, and CAD 5.3 million during the Q4, a 9% increase, as I mentioned a moment ago. We see continued solid adoption in the U.S. with sales increasing 42% for the year and up 25% for the quarter. These results were achieved despite a slightly negative impact from the third wave or Delta variant wave that came through the U.S. as hospitals slowed down once again during the June to August period. The summer months are traditionally slower in the Cath lab in the U.S., so in combination with the COVID-related case volume decrease, we are encouraged by the progress we made in the quarter. For the year, our concentrated efforts to expand and enhance our market share in the U.S. by adding new customers while capitalizing on the recent signing of two significant GPO contracts have been critical. Working with hospital systems and GPOs has been a key initiative, and we are excited with the progress made to drive market acceptance in the U.S. As a reminder, we signed our first U.S. GPO agreement in October 2020, providing access to the OptoWire to all their members across the U.S. In April 2021, we signed our second major GPO agreement with Vizient, one of the country's largest GPOs, to provide our OptoWire Prime to over 700 cath labs. As a result of signing these two GPO agreements, Opsens products are now an option for more than half of all U.S. cath labs. While still a relatively small amount, unit sales to GPOs grew 19% during Q4 2021 compared to Q2 2021 when we started with GPOs, with new accounts getting added each quarter due to the GPO's contract. We see this as a positive sign to the long-term potential these agreements can bring to us. Overall, we are confident that the work we have done during fiscal year 2021 positions us well to begin to build back the organization that will accelerate revenues and create the foundation for a successful SavvyWire product launch targeted for fiscal year 2023. Outside the U.S., sales performance was solid, with annual sales in EMEA up 21%, Canada was up 18%, and Japan was up 12%. Sales for the Q4 on a yearly comparable basis, EMEA was down 6%, Canada was up 22%, while Japan was up over 100% compared to the year-ago periods. However, similar to the U.S. market, we saw sequential impacts during the Q4 in Japan and EMEA due to the resurgence of COVID and other normal seasonality, as procedure numbers were down significantly during the June through August time frame. We are pleased those numbers seem to be rather normalized again in Q1 2022. As we touched a bit on last call, we achieved regulatory approvals for the OptoWire Prime, which should continue to be a key growth driver and improve gross margins due to manufacturing efficiencies going forward. We have talked about it in the past that OptoWire Prime new design is even more user-friendly, which we believe may increase its adoption with physicians and expand the assessment of coronary artery disease using FFR and dPR, which has the ability to result in better diagnosis and treatment for more patients. During the year, we also announced the signing of an agreement with Cath-medical Cardiovascular for the integration of our coronary physiology algorithms into their Picasso system, a next-generation hemodynamic system. The integration systems will initially focus on the Spanish cardiology market, where the Picasso has a dominant market share. This partnership agreement allows interventional cardiologists using this system to benefit from full integration into the cath lab and to offer superior diagnosis and treatment to their patients. We believe their integration brings together the best of both worlds, a more dynamic system and physiological guide wires, merging functionalities that will improve physician workflow, ease their decision-making process, and may lead to better patient outcomes. We are excited to see how this partnership develops. Transitioning to our business partnerships for a moment, where several companies are integrating Opsens sensors into their products used in medical applications, including Abiomed's integration of our pressure sensing technology into their Impella pump. Sales to OEMs were CAD 8.1 million in fiscal 2021, compared to CAD 8.3 million in fiscal 2020. For the quarter, it was CAD 2 million compared to CAD 2.3 million in the Q4 a year ago. For the quarter and fiscal year 2021, we saw some customers increasing mix of sensors versus signal conditioners. While this had negative effect on short-term revenues, it's positioning OEM revenues for growth in fiscal year 2022 and after. Overall, when you include our coronary artery disease business, plus the contribution from medical partnerships, our medical segment sales were up 15% to CAD 31 million during the fiscal year 2021, and up 4% to CAD 7.3 million for the Q4. Let us now discuss the performance of our industrial segment. For the year, this segment saw very nice performance, with revenue up 36% to CAD 3.4 million. For the quarter, it was approximately CAD 700,000, up 30%. As a reminder, our industrial segment leveraged our optical technology and knowledge through our wholly-owned subsidiary called Opsens Solutions, offering key solution in optical, temperature, pressure, strain, and other critical parameters for various industries, including aerospace, nuclear, and power electronics. I have repeatedly stated that I want to keep the near-term expectations guarded. However, looking ahead, the long-term opportunity in this segment continues to get more attractive as we are working on a number of potentially significant projects where Opsens' proprietary sensing components could be integrated into these critical projects. This includes the Eureka Network program, which is aiming to support development by Opsens and its partner, an optical fuel monitoring system for aerospace application based on Opsens Solutions' patented fibre optic technology. This innovative system is intended for use in commercial aircraft, among others, and is designed to be safer, lighter, and to reduce contaminant emissions. The other key project is the International Thermonuclear Experimental Reactor, or ITER Project. ITER is the world's largest nuclear fusion and scientific experiment project, with 35 nations currently under construction in Southern France. As a reminder, Opsens was selected to supply our customer with fibre optic, absolute and differential pressure sensor that will provide critical information for accurate monitoring of their cryogenic valve boxes. In total, it is anticipated that there will be a large number of sensors at different levels of the ITER project, for which Opsens sensing technology would be applicable for this important project. The team at Opsens Solutions continues to do a great job, and I look forward to the continued leveraging of our optical technology to a wide variety of commercial applications. With that overview on our commercial base operation, let's jump into our lead development program for TAVR. As I mentioned earlier in the call, we are leveraging our proprietary optical technology for the benefit of the multi-billion-dollar transcatheter replacement of the aortic valve, or TAVR market. Our TAVR guidewire allows for a single wire to diagnose and deliver the valve, potentially reducing complications, saving time and cost. It would be the industry's first guidewire that can deliver the valve and allow for continuous pressure measurement. Again, there are no other guide wires in the market that can do both of these functions. Which we believe will provide us with a significant competitive advantage in gaining market adoption of our SavvyWire. As I mentioned at the outset, we are extremely pleased to have completed our first-in-man study. The study was conducted on 20 patients in two world-renowned structural heart institutions led by Dr. Josep Rodés-Cabau at the Quebec Heart and Lung Institute in Quebec City, and Dr. Reda Ibrahim at the Montreal Heart Institute in Montreal as primary investigators. Sincerely, we would like to thank the entire team of those hospitals that have been key contributors to rapid completion of the study and allowed Opsens to better appreciate our benefits related to the SavvyWire concept. Opsens SavvyWire, while it's not approved for commercialization, was featured in four presentations by leading medical specialists during the Transcatheter Cardiovascular Therapeutics 2021 annual meeting, held from November 4 to November 6 in Orlando, Florida. First, Dr. Philippe Généreux, interventional cardiologist, world-renowned for his innovative research and director of the Structural Heart Program at Morristown Medical Center in New Jersey, led a panel of key opinion leaders to discuss the future of TAVR hemodynamics brought on by Opsens SavvyWire. The discussion focused on current unmet needs in the field of structural heart interventions, especially related to the need for more efficient, safe, and optimal way to assess procedural results during TAVR and the unique solution the Opsens SavvyWire provides for this important medical procedure. The symposium featured international physician experts, including Dr. Thomas Modine from CHU de Bordeaux, France, Dr. Hema Gada from UPMC Pinnacle, Pennsylvania, U.S., and Dr. Reda Ibrahim from Montreal Heart Institute in Canada. Next, Dr. Généreux presented for the first time clinical data validating the robustness of the Opsens SavvyWire algorithm in assessing pressure gradient before and after TAVR procedure, compared to different diagnostic modalities during two presentations. One titled A Validation Study of the Opsens Left Ventricle Pressure Guidewire, and a second title, Evaluation of the Opsens OptoWire Three and Its Novel TAVR Algorithm to Measure Pressure Gradient Before and After TAVR Compared with Hemodynamic Value Derived by Catheterization and Echocardiogram. Additionally, Dr. Josep Rodés-Cabau, cardiologist and hemodynamic specialist at Quebec Heart and Lung Institute in Canada, joined Dr. Généreux and other key opinion leader physicians to discuss innovation trends in TAVR technologies. Dr. Rodés-Cabau reported on his experience with Opsens SavvyWire as one of the lead investigators conducting our human study. We are extremely pleased that Opsens was prominently featured at this year's TCT annual meeting by an esteemed group of physicians as they presented their findings on the potential benefits of our technology for the TAVR market. This is a testament to the hard work and dedication of our team, and I appreciate their efforts. Again, the SavvyWire will be a 510(k) submission. In addition to completing the appropriate regulatory steps, we are also preparing to ramp up commercial production of the SavvyWire that will enable us to hit the ground running next year. We are extremely excited about the progress we have made and the potential opportunity our TAVR guidewire can bring to the market for improved patient outcomes. We remain on track to commercially launch our SavvyWire in calendar year 2022 and believe this has the ability to be a significant growth driver for the company for years to come. I look forward to sharing more with you in the coming months as we move closer to commercialization. Before I turn it over to Robin for a more detailed review of the financials, let me quickly summarize. Fiscal 2021 was a good year for Opsens as we reported record revenues led by our OptoWire product for coronary artery disease. These record revenues were achieved in the face of continued headwinds throughout parts of the year as pandemic slowed down the number of procedures conducted at certain hospitals around the world. This give us confidence for another record year in 2022. We completed our in-man study for TAVR and remain on track to commercialize this disruptive new technology in calendar year 2022. We have a number of large potential projects in the pipeline of our Opsens Solutions segment that could significantly drive growth in the future. We have a strong balance sheet that is allowing us to deploy resources to accelerate sales and marketing activities while increasing R&D investments to further capitalize on business opportunities ahead of us. We believe Opsens is in a unique position to create value going forward through accelerated revenue growth and the release of disruptive new products that can meet unmet needs for the best interest of physicians and patients. This is an exciting time for all of us at Opsens. As always, I want to thank all our employees for their hard work and dedication as we truly have accomplished a number of very important milestones and developments. There continues to be a lot of work ahead of us, but I am confident we are up to the challenge. Let me now turn the call over to Robin for a further review of the financial results. Robin? Thank you, Louis, and thanks to everyone joining us on the call. As we hit on a few of these items, I will try to add some additional details where I can. The company reported record annual sales of CAD 34.5 million in fiscal 2021 compared to CAD 29.5 million in fiscal 2020. This was broken down as CAD 22.9 million in our coronary artery disease line of business or FFR, dPR, CAD 8.1 million in our optical medical systems, which is mainly our agreement with Abiomed for integration of our pressure sensor into their Impella pump, and CAD 3.4 million in our industrial or Opsens Solutions segment. For the Q4 of fiscal 2021, revenue was CAD 8.1 million compared to CAD 7.6 million. This was broken down as CAD 5.3 million in our coronary artery disease line of business, CAD 2 million in our optical medical systems, and CAD 700,000 in our industrial segment. As we stated a year ago, quarterly revenues were certainly impacted by procedure slowdowns due to the ongoing pandemic. While we were back to more normalized levels throughout much of our fiscal 2021, we did see an impact again during the Q4 as the Delta variant or third wave rolled through. We are once again seeing procedures increase here in the Q1. On an annual basis, we did see growth in all four of our key markets, including the U.S., EMEA, Japan, and of course, Canada. Our Opsens Solutions business continues to see an increase of orders, particularly from the nuclear segment. Our OEM revenues should maintain constant growth. I mentioned this last quarter, but one important item to note, the company's revenues are generated in U.S. dollars, Canadian dollars, euros, and British pounds. Fluctuation in the exchange rate affect revenues. For the three-month period ended August 31, 2021, revenues were negatively affected by about CAD 450,000 compared to the same period last year. In contrast, sales were positively impacted by CAD 10,000 for the three-month period ended August 31, 2020. When you look at gross margin, they were up 100 basis points for the year to 54% compared to 53%. For the quarter, they were flat at 50%. We continue to believe we will see year-over-year increase in gross margin percentage due to higher sales volume and the related economies of scale, combined with enhanced productivity and by lower cost of goods sold for OptoWire III compared to OptoWire II. From an operating expenses standpoint, as planned, overall operating expenses increased by CAD 1.5 million during the Q4 of fiscal 2021 compared to the Q4 of fiscal 2020. The increase is largely explained by our investments in sales and marketing as we are ramping up our sales efforts to continue growing market share in the U.S., along with increases in our general and administrative costs pertaining to higher headcount and professional fees. As we explained, we are making additional investments in sales and marketing and research and development over the coming quarters to capitalize on the opportunities we have to accelerate growth of OptoWire and development of our SavvyWire. For the year, operating expenses were relatively flat as the H1 of 2021 saw a reduction in expenses due to the reduced travel, et cetera. However, the back half saw the increases I just mentioned. EBITDA, which we define as net income loss plus financial expenses, depreciation of PP&E and right of use assets, amortization of intangible assets and stock-based compensation costs, was a negative CAD 0.7 million in the Q4 of 2021 compared to a positive CAD 1.4 million in the Q4 of 2020. The decrease in the Q4 is mainly due to higher sales and marketing and administrative expenses and a higher amount of CEWS Canadian grant received last year. Looking at net income, we are reporting a net loss of CAD 1.2 million in the Q4 of 2021 compared with a net income of CAD 0.6 million in the year ago Q4. The net loss is due to our investment to capitalize on business opportunities with additional spending in sales and marketing, R&D, and others for operating expenses increasing CAD 1.5 million, as I mentioned. We also had a CAD 900,000 Canadian grant last year, which was not recognized in this year's Q4. For the year, net loss was also CAD 1.2 million compared to a loss of CAD 2.6 million, an improvement of CAD 1.4 million. Finally, on the balance sheet, we ended August with CAD 38.6 million of cash and cash equivalents. Subsequently, to the end of our 2021 fiscal year in September 2021, the company prepaid the entire balance of the term loan in the amount of CAD 5.8 million, which will provide an annualized savings of approximately CAD 250,000. With that, I will turn the call over to Louis. Thank you, Robin. Thank you to all our investors for their continued interest and support of Opsens. We are working hard every day to capitalize on the opportunities ahead of us to position Opsens for long-term success. Operator, let me now turn the call over to any questions. We will now begin the question and answer session. To ask a question, you may press star then one on your touch tone phone. If you are using a speakerphone, please pick up your handset before pressing the keys. To withdraw your question, please press star then two. Our first question today comes from Rahul Sarugaser with Raymond James. Good morning, Louis and Robin. Thanks so much for taking my questions. Congratulations on completion of the TAVR trial and also congratulations on finishing 2021 strong. I just wanted to follow up a little bit more on the TAVR trial now that you've completed recruitment. You know, can you give us a little more clarity, if possible, on when we expect to see data? Assuming that that data is positive, strong, safe, you know, what the timelines look like around Health Canada and FDA submissions. Okay. Good morning, Rahul. Thanks for your question. First, I want to mention that at the last TCT conference, there was a presentation from Dr. Josep Rodés-Cabau from IUCPQ, where he presented one patient, one case that was performed during the study. Regarding the results of the study, I mean, for us, and I want to be very clear about this, the study is completed. There was no, let's say, in terms of the goal, the endpoint of the study, there is no follow-up required. We are now blitzing to gather all the data and we should get a final report on the study, hopefully, somewhere next week. It means that Opsens is expecting to be able to file for regulatory approval for Canada and U.S. somewhere next week, which is an advance to what we mentioned in the last call. And regarding the results of the study, I'm sure there would be different publications down the road by the doctors. This being said, it was a safety study where the endpoint was about does the SavvyWire was able to deliver the valve in the procedure. Does the SavvyWire was able to do what we call heart stimulation or rapid pacing? And does the SavvyWire was able to show accurate measurement during the procedure? On all those three topics, even if we have not received the final report yet, we feel that it was very successful. This has been giving an increased confidence to us that, I mean, there would be a place for the SavvyWire in the TAVR market. I don't know if this answers your question. I think it absolutely did answer my questions. Congratulations on the anticipated results. Assuming, you know, these timelines continue to be, you know, you can continue to hit these timelines, we would guesstimate that approvals would likely come through sometime middle of next year. Now, looking forward to a commercial plan, have you started to put this together given the, you know, competitive landscape with primarily Medtronic and Boston Scientific being two heavyweight players in the space? You know, can you give us any colour in terms of your forward thinking on that commercial plan? Well, sure. First on the approval, obviously there is a part of the timing that is out of our control. It will be in the hands of Health Canada and the FDA to analyse our file and to potentially clear us for commercialization. We are very confident that we've done all the proper validation work. Thinking that we should get, you know, end of the summer the approval in U.S. is certainly a reasonable assumption. We think there is a probability to get this earlier for Canada since Health Canada had the opportunity to review before granting us the go ahead for the first in-man study. They had the opportunity to review a good number of our validation testing and our validation plan. Once this is completed, once we get clearance for commercialization, I mean, right now we are increasing the size of our sales team to be able to properly support the launch of the SavvyWire. We expect to double the size of our sales team from what we are having today. Regarding the, let's say, at higher level in terms of the marketing strategy, we are adding some resources to the team. We are also having multiple discussions with key opinion leaders in the field to make sure that we come with the proper value proposition messaging. We think that, again, we are going after a very significant market opportunity. The feedback that we are getting right now, following the first-in-man study, following multiple presentations at TCT, is giving us great confidence that it will be, I mean, the launch of the SavvyWire will be a transformational event for Opsens because we'll move from a single product company that we sell directly to the hospital to having a second product in our bag. This will make us more relevant for our customers, more relevant for doctors, more relevant for GPOs, and it will help us also to make our sales force much more efficient. Great. Thanks, Louis. I'll just ask one quick follow-up question. In terms of when you get to that commercial stage, do you anticipate running any additional clinical studies to illustrate the benefits of SavvyWire over standard of care? If so, do you have any sense of what those trials may cost? The answer is absolutely yes. We have not finalized yet our clinical plan. Once we will do this, we'll share this in greater detail with the financial market. For sure, I mean, right now we are gathering all the learning that we get from the first-in-man. We are having multiple discussions with key opinion leaders in the field because, here, I mean, it's completely different than when we came with the OptoWire. The OptoWire is, under our opinion, the best product in the market, achieving, let's say similar functions than competitors. While in the case of the SavvyWire, we are coming with a completely new concept. There are opportunities to do clinical work that will really make more tangible the benefits, the potential benefits that we could have for doctors, patients and hospitals. What would be the amount of this? We are certainly talking about, you know, probably in the range of CAD 3 million to CAD 5 million that would be spent once the product is commercialized. Again, this decision has not been made. It will be influenced by the feedback that we get from the most influential doctors in the TAVR field. Great. Thanks, Louis-Robert for taking our questions. Congratulations again on the strong year, and we'll get back in the queue. Thank you very much, Rahul. Our next question comes from Justin Keywood with GMP Securities. Hi, good morning. Thanks for taking my call. Just a question on the OptoWire. There was comments in your opening remarks that there was less procedures in the quarter due to the variance in the spread of COVID-19. I know there's a large backlog of procedures that still need to be done. Is the way to look at the quarter and the lower growth as just a temporary blip just due to the spread and the increased cases to what you know has been you know pretty good growth resuming you know coming out of the early days of the pandemic? If that's true, should we see the current quarter we're in having a rebound to you know what the rates were subsequent to the results? For sure, we are expecting to see a certain rebound in Q1 2022, so I'm talking about the period from September 1, 2021 to November 30, 2021. The Street should expect some growth. This being said, there would still be a certain impact from COVID. We don't expect Q1 to be what we would see a more normal quarter. This being said, when we are looking for the fiscal year 2022, we expect to record good growth and obviously stronger growth than what we've seen in Q4 2021. Okay. That's helpful context. For that outlook, would that include material traction with the recent GPOs that were signed, or does that take a little while to penetrate those relationships? I mean, no. There would be a positive impact from the relationships that we built with a group purchasing organization. This will be combined also with, I mean, a broader team to really capitalize on the benefits of the OptoWire. Because, I mean, coming back from TCT this year, again, we got very good interest around the OptoWire. Opsens is putting in place the right team to be able to reach more physicians that would benefit from having the OptoWire in their hands. Okay, thank you. I just had a couple questions on the SavvyWire. Just to clarify, the Health Canada submission could come next week in conjunction with data around the trial being disclosed. Is that correct? Well, regarding the filing for Health Canada and the FDA, yes, we expect to complete this next week. Regarding data, I'm, you know, I mean, I don't expect Opsens to release any specific data on this study that was mostly a safety study. If you want to look at some interesting data around the SavvyWire, you can refer to two presentations that were made at TCT this year by Dr. Philippe Généreux from Morristown regarding the interest of the pressure measurement that we are going to provide with the SavvyWire. Once we get the approval on the product, we'll do, as I mentioned in the first set of questions, we'll do multiple clinical studies to further demonstrate the value proposition of the SavvyWire. Okay. Just on the endpoints you mentioned earlier in the call, you know, that the SavvyWire does have the ability to do the rapid pacing and successfully delivering the valve. I assume if there's the submission to the FDA and Health Canada next week that those endpoints would be met, if I'm reading that correctly. That's our understanding. Opsens has been attending to all cases performed during this first in-man study. That's our opinion on the subject. As I mentioned, we have not received the official report yet from the principal investigator, but we are confident that all endpoints have been met. Okay, great. Well, we'll look forward to those developments, and thank you for taking my questions. Thank you, Justin. Our next question comes from Brian Gagnon with Gagnon Securities. Good morning, Louis. I have a couple of questions for you. You've had some recent changes in your sales force, and I know you said on the call that you were planning to double the size of the sales force. Can you give us a little more idea as to how the sales force is gonna be expanding in the U.S. and what particular markets they're gonna be going into? I mean, if you recall when COVID first hit, Opsens adjusted its sales organization to do more work at distance and reaching out to doctors using technology. Now that, I mean, we are hoping that this period will somehow evolve to a more normal situation. There are various markets where Opsens is not actively present. I mean, those markets are in different states in U.S. We will expand the sales force with a geographical approach driven by data that PCI number and so on. also, I mean, as I mentioned, we feel we are building right now a stronger broader organization with new leadership in sales. We are confident that the early positive results that we are seeing will also be translated into a stronger growth for the fiscal year 2022. Great. How do you guys think about sales productivity? Are there specific metrics that you guys are using? Do you have quotas installed at this point? What's the overall thought process for sales productivity for the company? It's certainly, I mean, sales per territory manager is a key indicator for us. Even, I mean, when we compare to figures that we got before, in the last year, the productivity from our sales people more than doubled. We see still the opportunity to do better. In addition, we think that once we will add a second product like the SavvyWire to our portfolio, we'll be able to sell this product to the same customer as what we have today. Again, this will be another enhancement on the productivity that we get from our sales representatives. I would say high level key indicators are sales per person and you know with certain clear targets to bring those territory manager to profitability. Because once we do this, it's allowing us to add more people. Excellent. Last question for me. During the trial, I know it's only 20 patients, and congrats on hitting the endpoints. Did you see any time savings? Not necessarily overall, but as the docs were using it, you know, the first case always takes longer. By the time they were progressing and getting more comfortable using it, did the doctors see any real time savings by using the SavvyWire versus the traditional methods? Interesting question. Anything anecdotal would be fine. Yeah. Well, Brian, we saw an improvement, let's say, from patient number one to patient number 20 under the protocol that we were running for the first-in-man. The protocol that we were running was not exactly, let's say, the standard of care that we will have in a normal procedure down the road. Certainly, I mean, when we think about the value proposition of the SavvyWire, the fact that we can eliminate some steps that we can eliminate some insertion, I'll just take the example of the rapid pacing. This is potential direct time savings. In summary, what I would say after seeing the 20 patients, are confident that the time savings will be relevant for our customers increase over those 20 patients. Terrific. Thank you. Look forward to that. Thank you, Brian Gagnon. This concludes our question and answer session. I'd like to turn the call back over to management for some closing remarks. Well, again, I want to thank everybody that attended this conference call. Opsens is incredibly excited about its future, both with the OptoWire, the SavvyWire, but also the OEM business that we have with the customers that are growing, also with the industrial business that is going to transform the world, regarding the fuel monitoring for aerospace. In summary, I want to thank all the support from the shareholders. I also want to thank all the employees that are devoting a great efforts to develop great products to meet the need of the market. With that, I wish you a Happy Thanksgiving to all of our American listeners. The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.